CDS2015:两项真实世界的糖尿病研究结果发布

2015-12-12 李妍 整理 中国医学论坛报

1.IntroDia研究对我国糖尿病管理的启示 作者:北京大学人民医院纪立农 糖尿病患者确诊后首次接触医生以及在之后就诊过程中会面临很多问题。IntroDia研究即2型糖尿病患者早期对话研究是首次探讨在更好地管理、控制糖尿病过程中,非药物因素所起作用的研究。该研究于2013年12月2日启动,为迄今全球最大规模的糖尿病跨国统计调查,将纳入逾万例自报和确诊的2型糖尿病患者,涉及26个国家650

1.IntroDia研究对我国糖尿病管理的启示

作者:北京大学人民医院纪立农

糖尿病患者确诊后首次接触医生以及在之后就诊过程中会面临很多问题。IntroDia研究即2型糖尿病患者早期对话研究是首次探讨在更好地管理、控制糖尿病过程中,非药物因素所起作用的研究。该研究于2013年12月2日启动,为迄今全球最大规模的糖尿病跨国统计调查,将纳入逾万例自报和确诊的2型糖尿病患者,涉及26个国家6500余名医生,调查医患之间在确诊和改良治疗时的对话,包括患者在就诊时得到的信息、患者的期望,医生给予患者的信息、有无达到预期效果、面临的挑战等。此外,调查还将研究这些早期对话如何对患者预后产生影响,呼吁医生开展2型糖尿病确诊时的早期对话,并关注具有改善预后潜力的要素,优化医患之间的沟通。

2型糖尿病早期对话是医生和糖尿病患者之间对疾病治疗最初期的交流。研究显示,这种早期对话确定了2型糖尿病患者未来治疗的基调。有建设性的早期对话可以提高糖尿病患者的信心,增进患者对相关知识的了解和监测血糖的动力,有利于患者遵循医嘱治疗、改变生活方式,并改善整体健康状况和长期结果。同时,早期对话还为医生提供了一个平台,帮助患者解决已形成的对2型糖尿病的疑虑、预期和误解。

糖尿病管理的复杂性和中国的实际情况呼吁简化治疗,实现医患轻松,这不仅是医患者共同的心声,也是未来糖尿病治疗发展的必然趋势。影响早期对话的因素主要有:时间不够,疾病复杂,情感和心理障碍,文化、家庭、社会和宗教等因素的影响等。

如何促进早期对话?首先,医生与2型糖尿病患者之间要建立共同的目标;其次,医生要了解患者的预期,并巧妙地将医生的目标融进去,从而建立成功的合作伙伴关系。如何与患者沟通应成为每位医生职业培训的一部分,以保证患者获得信息的一致性。

现代糖尿病治疗理念主张全程管理,在早期对话中,应关注2型糖尿病患者的低血糖风险、体重控制、心血管及肝肾功能改善,以及服药依从性和便利性等。这种全程管理的理念也得到了国内外权威指南的推荐。(李妍整理,纪立农教授审校)

邹大进带字.png

2.体重与2型糖尿病控制的实效研究

作者:第二军医大学附属长海医院陈榕邹大进

肥胖是2型糖尿病重要发病危险因素和伴随状态。中国2型糖尿病患者近60%合并超重或肥胖。

为了解中国2型糖尿病特别是肥胖2型糖尿病患者的诊疗现状,我们开展了全国性调查,以评估我国2型糖尿病门诊患者的血糖控制情况,以对2型糖尿病患者的综合管理提供参考。

研究在全国26个医学中心进行。2010年8月至2012年4月间共纳入2型糖尿病门诊患者9644例。通过问卷收集患者一般情况、血糖、血脂、血压达标、用药及合并症与并发症等信息。患者入选标准为确诊2型糖尿病、年龄>18岁、体质指数(BMI)>18kg/m2。据BMI进行分层。糖化血红蛋白(HbA1c)≤7%或空腹血糖(FPG)<7.0mmol/L为血糖控制达标。

研究共纳入9065份有效样本数据,其中,男性5035例,女性4030例。所有患者的血糖控制率仅有32.6%,而血糖、血压、血脂三项指标同时达标者仅占11.2%。BMI<24、24~28和>28kg/m2患者分别为2939例、3361例和2764例;血糖控制率分别为33.7%、33.8%和30.2%;血糖、血压、血脂三项指标同时达标率分别为12.8%、12.1%和8.5%;在年龄≥75岁患者中,不同BMI组的达标率差异显著。BMI<24kg/m2组达标率最高,BMI>28kg/m2组最低;超重和肥胖患者糖尿病视网膜病变、神经病变、肾病等微血管并发症患病率未见明显升高,但冠心病患病率显著增加,各BMI组分别为12.2%、15.7%和15.9%。

多因素Logistic回归分析显示,年龄大、高BMI、教育程度较低及糖尿病病程短均是影响血糖达标的主要危险因素。

总之,门诊2型糖尿病患者血糖控制率较低,肥胖者血糖、血压、血脂控制率最低。超重和肥胖患者微血管并发症患病率未见明显升高,但肥胖患者冠心病、高血压患病率较高。年龄大、高BMI、教育程度较低及糖尿病病程短均是影响血糖达标的主要危险因素。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1739427, encodeId=35a21e3942700, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Mon Oct 31 13:42:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48471, encodeId=d15d484e110, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:18:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295151, encodeId=a5ed129515140, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Mon Dec 14 14:42:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377587, encodeId=7aeb13e758723, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Dec 14 14:42:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46067, encodeId=4e7f4606e5f, content=依从性太差, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Mon Dec 14 07:35:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45777, encodeId=586845e77a3, content=……………, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:26:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45748, encodeId=3fd945e488c, content=糖尿病加强盖管理,提高治疗依从性很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24721662825, createdName=1ddf23d5m57(暂无匿称), createdTime=Sun Dec 13 04:02:00 CST 2015, time=2015-12-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1739427, encodeId=35a21e3942700, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Mon Oct 31 13:42:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48471, encodeId=d15d484e110, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:18:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295151, encodeId=a5ed129515140, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Mon Dec 14 14:42:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377587, encodeId=7aeb13e758723, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Dec 14 14:42:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46067, encodeId=4e7f4606e5f, content=依从性太差, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Mon Dec 14 07:35:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45777, encodeId=586845e77a3, content=……………, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:26:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45748, encodeId=3fd945e488c, content=糖尿病加强盖管理,提高治疗依从性很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24721662825, createdName=1ddf23d5m57(暂无匿称), createdTime=Sun Dec 13 04:02:00 CST 2015, time=2015-12-13, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    好文章,值得看。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1739427, encodeId=35a21e3942700, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Mon Oct 31 13:42:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48471, encodeId=d15d484e110, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:18:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295151, encodeId=a5ed129515140, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Mon Dec 14 14:42:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377587, encodeId=7aeb13e758723, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Dec 14 14:42:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46067, encodeId=4e7f4606e5f, content=依从性太差, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Mon Dec 14 07:35:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45777, encodeId=586845e77a3, content=……………, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:26:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45748, encodeId=3fd945e488c, content=糖尿病加强盖管理,提高治疗依从性很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24721662825, createdName=1ddf23d5m57(暂无匿称), createdTime=Sun Dec 13 04:02:00 CST 2015, time=2015-12-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1739427, encodeId=35a21e3942700, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Mon Oct 31 13:42:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48471, encodeId=d15d484e110, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:18:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295151, encodeId=a5ed129515140, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Mon Dec 14 14:42:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377587, encodeId=7aeb13e758723, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Dec 14 14:42:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46067, encodeId=4e7f4606e5f, content=依从性太差, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Mon Dec 14 07:35:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45777, encodeId=586845e77a3, content=……………, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:26:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45748, encodeId=3fd945e488c, content=糖尿病加强盖管理,提高治疗依从性很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24721662825, createdName=1ddf23d5m57(暂无匿称), createdTime=Sun Dec 13 04:02:00 CST 2015, time=2015-12-13, status=1, ipAttribution=)]
    2015-12-14 yangpeizhi
  5. [GetPortalCommentsPageByObjectIdResponse(id=1739427, encodeId=35a21e3942700, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Mon Oct 31 13:42:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48471, encodeId=d15d484e110, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:18:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295151, encodeId=a5ed129515140, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Mon Dec 14 14:42:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377587, encodeId=7aeb13e758723, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Dec 14 14:42:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46067, encodeId=4e7f4606e5f, content=依从性太差, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Mon Dec 14 07:35:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45777, encodeId=586845e77a3, content=……………, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:26:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45748, encodeId=3fd945e488c, content=糖尿病加强盖管理,提高治疗依从性很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24721662825, createdName=1ddf23d5m57(暂无匿称), createdTime=Sun Dec 13 04:02:00 CST 2015, time=2015-12-13, status=1, ipAttribution=)]
    2015-12-14 老段

    依从性太差

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1739427, encodeId=35a21e3942700, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Mon Oct 31 13:42:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48471, encodeId=d15d484e110, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:18:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295151, encodeId=a5ed129515140, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Mon Dec 14 14:42:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377587, encodeId=7aeb13e758723, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Dec 14 14:42:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46067, encodeId=4e7f4606e5f, content=依从性太差, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Mon Dec 14 07:35:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45777, encodeId=586845e77a3, content=……………, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:26:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45748, encodeId=3fd945e488c, content=糖尿病加强盖管理,提高治疗依从性很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24721662825, createdName=1ddf23d5m57(暂无匿称), createdTime=Sun Dec 13 04:02:00 CST 2015, time=2015-12-13, status=1, ipAttribution=)]
    2015-12-13 yuwenpsy

    ……………

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1739427, encodeId=35a21e3942700, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Mon Oct 31 13:42:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48471, encodeId=d15d484e110, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:18:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295151, encodeId=a5ed129515140, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Mon Dec 14 14:42:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377587, encodeId=7aeb13e758723, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Dec 14 14:42:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46067, encodeId=4e7f4606e5f, content=依从性太差, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Mon Dec 14 07:35:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45777, encodeId=586845e77a3, content=……………, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:26:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45748, encodeId=3fd945e488c, content=糖尿病加强盖管理,提高治疗依从性很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24721662825, createdName=1ddf23d5m57(暂无匿称), createdTime=Sun Dec 13 04:02:00 CST 2015, time=2015-12-13, status=1, ipAttribution=)]
    2015-12-13 1ddf23d5m57(暂无匿称)

    糖尿病加强盖管理,提高治疗依从性很重要

    0

相关资讯

EHJ:真实世界研究显示利伐沙班在非瓣膜性房颤患者中大出血率低(XANTUS研究)

●来自4万5千名非瓣膜性患者参加的真实世界研究结果证实拜瑞妥的出血率低 ●ROCKETAF试验的扩展试验XANTUS结果表明拜瑞妥在高和低风险患者中都提供高效卒中预防效果 ●正在进行的上市后安全性监测试验两年结果表明主要出血事件的发生率和发生形式与ROCKETAF试验一致 两个真实世界研究结果,分别是XANTUS试验和一项上市后安全性监测研究(PMSS),两个试验都表明Xa因子抑制剂拜瑞妥(

真实世界研究与随机对照试验、单病例随机对照试验在临床治疗性研究中的关系比较

临床工作及其研究是十分复杂的过程。不同个体虽患同种疾病,但临床表现互有差异,且临床反应的变化也不尽相同。因此,无法获得同一干预措施下不同个体的相同治疗效果;加之有的治疗措施缺乏真实性和实用价值,从而使得疗效评价成为一个难题。近些年来,普遍采用试验性的研究结果作为证据指导临床实践活动,其中以随机对照试验(RCT)最为受到重视,但由于RCT属于药物面市前研究,对研究对象的选择、治疗措施的应用等均有

Int J Clin Pract:真实世界研究显示伐尼克兰辅助戒烟安全有效

  中国学者的一项研究证明了伐尼克兰在真实环境中用于亚洲成年人戒烟的有效性和安全性,并与伐尼克兰随机对照试验的结果相一致。相关论文发表于《国际临床实践杂志》 (Int J Clin Pract.)。  该多中心、前瞻性、非比较性的观察研究从中国、印度、菲律宾和韩国共纳入1377名受试者,1373(99.7%)名患者接受伐尼克兰,并对安全性和有效性进行了评估。试图戒烟的成人吸烟者与调查人员

Br J Radiol:大规模真实世界研究显示碘克沙醇的临床安全性

   2013年12月19日,由同济大学附属上海第十人民医院心内科徐亚伟教授牵头的95个医学中心、20,185例中国患者使用等渗对比剂碘克沙醇的上市后监测研究临床试验结果首次全文发表于英国放射学会唯一官方期刊《英国放射学杂志》。    “随着血管造影和 PCI 新技术的快速发展,其适应证也在不断地扩展,介入手术量随之呈现几何级数增长。与此同时,PCI

真实世界研究与随机对照试验、单病例随机对照试验的比较

由于随机对照试验(RCT)在实际临床研究中存在一定的困难性,近年来真实世界研究(real world research, RWR)引起了医务工作者的关注。在此对RWR与RCT、单病例随机对照试验(number of one randomized controlled trial, NORCT)之间的关系作一比较。并对蓝鱼老师热情提供相关资料文献表示感谢。RWR起源于实用性临床试验,属于

实证研究/真实世界研究的功效与局限

20世纪80年代以来,实证研究在中国的社会研究中逐步被本土研究者所广泛采用,尤其中国社会学界对实证研究给予了高度重视,从而为解决中国社会的相关问题起到了不可低估的作用。实证研究之所以能在社会科学的各个领域得到广泛使用,是由其本身固有的优势所决定。当然,任何一种研究也有其局限性,实证研究也不例外。在临床上,近年来流行的真实世界研究,包括登记数据库研究,都属于实证研究,与经典的随机对照研究不同,更接近